Atmosphere1 / Shutterstock.com
28 September 2020AmericasSarah Morgan
MSD petitions SCOTUS over $2.5bn patent verdict
MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
4 February 2020 Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Asia-Pacific
15 October 2020 In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.
Big Pharma
21 January 2021 A subsidiary of MSD has failed to revive a record $2.5bn verdict against Gilead Sciences, after the US Supreme Court refused to hear arguments that a patent was improperly invalidated.
Editor's picks
Editor's picks
Americas
4 February 2020 Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Asia-Pacific
15 October 2020 In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.
Big Pharma
21 January 2021 A subsidiary of MSD has failed to revive a record $2.5bn verdict against Gilead Sciences, after the US Supreme Court refused to hear arguments that a patent was improperly invalidated.
Americas
4 February 2020 Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Asia-Pacific
15 October 2020 In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.
Big Pharma
21 January 2021 A subsidiary of MSD has failed to revive a record $2.5bn verdict against Gilead Sciences, after the US Supreme Court refused to hear arguments that a patent was improperly invalidated.